Camptothecin poly[N-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: Intratumor release and antitumor efficacy

Molecular Cancer Therapeutics

Volumn 2, Issue 1, 2003, Pages 29-40

  Zamai, Moreno ^a   VandeVen, Martin ^b,e   Farao, Mariella ^a   Gratton, Enrico ^c   Ghiglieri, Alberto ^a   Castelli, Maria G ^a   Fontana, Erminia ^a   D'Argy, Roland ^a,f   Fiorino, Antonio ^a   Pesenti, Enrico ^a   Suarato, Antonino ^a   Caiolfa, Valeria R ^d  

^a PFIZER INC   (United States)

^b ISS   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e HASSELT UNIVERSITY   (Belgium)

^f Active Biotech Research AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; ESTER; METHACRYLIC ACID DERIVATIVE; METHACRYLOYLGLYCYLGLYCINE 4 NITROPHENYL ESTER; METHACRYLOYLGLYCYLGLYCINE-4-NITROPHENYL ESTER;

ANIMAL; ARTICLE; BREAST TUMOR; FEMALE; HUMAN; LUNG TUMOR; MALE; MOUSE; NUDE MOUSE; PROSTATE TUMOR; SPECTROFLUOROMETRY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; XENOGRAFT;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; ESTERS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METHACRYLATES; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0141857672     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wall, M., Wani, M., Cook, C., Palmer, K., McPhail, H., and Sim, G. Plant antitumor agents: The isolation and structure of camptothecin, a novel alkaloidal leulemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
2. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. Part 1, 54: 461-470, 1970.
3. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and Sealwry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515-521, 1972.
4. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
5. Hsiang, Y. H. Wu, H. Y., and Liu, L. F. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem. Pharmacol., 37: 1801-1802, 1988.
6. Kohn, K. W., and Pommier Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. N. Y. Acad. Sci., 922: 11-26, 2000. (Pubitemid 32050238)
7. Jung, L. L., and Zamboni, W. C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist Updat., 4: 273-288, 2001.
8. Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989. (Pubitemid 19208330)
9. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Wash. DC), 246: 1046-1048, 1989. (Pubitemid 20010531)
10. Potmesil, M., Hsiang, Y. H., Liu, L. F., Bank, B., Grossberg, H., Kirschenbaum, S., Forlenza, T. J., Penziner, A., and Kanganis, D., Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. (Published erratum appears in Cancer Res., 48: 4716, 1988). Cancer Res., 48: 3537-3543, 1988.
11. Hertzberg, R. P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase-I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629-4638, 1989. (Pubitemid 19151036)
12. Jaxel, C., Kohn, K., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989. (Pubitemid 19088683)
13. Champoux, J. J. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann. N. Y. Acad, Sci., 922: 56-64, 2000. (Pubitemid 32050241)
14. Potmesil, M., Giovanella, B. C., Liu, L. F., Wall, M. E., Silber, R., Stehlin, J. S. Hsiang, Y-H., and Wani, M. C. Preclinical studies of DNA topoisomerase I-targeted 9- amino and 10, 11-Methylenedioxy camptothecins. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, Chapter 23, pp. 299-311. New York, NY: Oxford University Press, 1991.
15. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168, 1991.
16. Rowinsky, E., Grochow, L., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., and Kaufmann, S. H. Phase I and pharmacologic study of topotecan (SK&F 104864): a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
17. O'Leary, J., and Muggia, F. M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer, 34: 1500-1508, 1998. (Pubitemid 28446329)
18. Kehrer, D. F., Soepenberg, O., Loos, W. J., Verweij, J., and Sparreboom, A. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs, 12: 89-105, 2001. (Pubitemid 32207358)
19. Kopecek, J., Kopeckova, P., Minko, T., and Lu, Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm., 50: 61-81, 2000. (Pubitemid 30326689)
20. Maeda, H., Seymour, L. M., and Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem., 3: 51-362, 1992.
21. Nugent, L. J., and Jain, R. K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res., 44: 38-244, 1984.
22. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 55: 3552-3756, 1995.
23. Maeda, H. Polymer conjugated macromolecular drugs for tumorspecific targeting. In: A. J. Domb, (ed.), Polymeric Site-specific Pharmacotherapy, pp. 95-116. New York: J. Wiley, 1994.
24. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumouritropic accumulation or proteins and the antitumour agent SMANCS. Cancer Res., 46: 6387-6392, 1986. (Pubitemid 17221789)
25. Seymour, L. W., Ulbrich, K., Steyger, P. S., Brereton, M., Subr, V., Strohalm, J., and Duncan, R. Tumour tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F19 melanoma. Br. J. Cancer, 70: 636-641, 1994. (Pubitemid 24305589)
26. Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P., and Kopecek, J. Degradation of side-chains of N-(2-hydroxyproply)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep., 2: 1041-1046, 1983. (Pubitemid 13154918)
27. Duncan, R. Polymer-drug conjugates: potential for improved chemotherapy. Anticancer Drugs, 3: 175-210, 1992.
28. Cassidy, J., Duncan, R., and Morrison, G. J., Strohalm, J., Plocova, D., Kopecek, J., and Kaye, S. B. Activity of N-(2-hydroxyproply)methacryamide copolymers containing daunomycin against a rat tumor model. Biochem. Pharmacol., 38: 875-879, 1989. (Pubitemid 19074656)
29. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Res. Campaign Phase I/II Committee. Clin. Cancer Res., 5: 83-94, 1999. (Pubitemid 29045181)
30. Caiolfa, V. R., Zamai, M., Fiorino, A., Frigerio, E., Pellizzoni, C., d'Argy. R., Ghiglieri, A., Castelli, M. G., Farao, M., Pesenti, E., Gigli, M., Angelucci, F., and Suarato, A. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J. Control Release, 65: 105-119, 2000.
31. Mendichi, R., Rizzo, V., Gigli, M., and Giacometti Schieroni, A. Molecular characterization of polymeric antitumour drug carriers by size exclusion chromatography and universal calibration. J. Liq. Chromatogr. and Rel. Technol., 19: 1591-1605, 1996. (Pubitemid 26201454)
32. Mendichi, R., Rizzo, V., Gigli, M., Razzano, G., Angelucci, F., and Giacometti Schieroni, A. Molar mass distribution of a polymer-drug conjugate containing the antitumour drug paclitaxel by size exclusion chromatography and universal calibration. J. Liq. Chromatogr. and Rel. Technol., 21: 1295-1309, 1998. (Pubitemid 28259018)
33. Lakowicz, J. R. Measurement of Fluorescence Lifetimes. In: Principles in Fluorescence Spectroscopy, pp. 52-89. New York, NY: Plenum Press, 1983.
34. Lakowicz, J. R., Laczko, G., Cherek H, Gratton E., and Linkeman M. Analysis of fluorescence decay kinetics from variable-frequency phase shift and modulation data, Biophys. J., 46: 463-477, 1984.
35. Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., and Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer, 81: 1318-1327, 1999.
36. Geran, R. I., Greenberg, N. H., MacDonald, M. M., Schumaker, A. M., and Abbott, B. J., Protocols for screening chemical agents and natural products against animal tumors and other biological systems (Ed. 3). Cancer Chemother. Rep., 3: 1-103, 1972.
37. National Cancer Institute. Division of Cancer Treatment. In: Development Therapeutics Program Instructions No. 14. Bethesda, MD: Information Technology Branch, National Cancer Institute, 1985.
38. Ahmed, A. E., Jacob, S., and Au, W. W. Quantitative whole body autoradiographic disposition of glycol ether in mice: effect of route of administration. Fundam. Appl. Toxicol., 22: 266-276, 1994. (Pubitemid 24089171)
39. Ahmed, E. A., S. Jacob, S., Giovanella, B. C., Kozielski, A. J., Stehlin, J. S., and Liehr, J. G. Influence of route of administration on [3H]camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother. Pharmacol., 39: 122-130, 1996. (Pubitemid 26400670)
40. Mi, Z., and Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325-10336, 1994. (Pubitemid 24281798)
41. Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am., 271: 58-65, 1994.